Clinical Study of Targeted Programmed Death Ligand-1 (PD-L1) Molecular Probe

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600118309

Enrollment

Unknown

Registered

2026-02-04

Start date

2026-03-02

Completion date

Unknown

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

Group A: 18F-PDL1P and 18F-FDG PET imaging group:Injection of 18F-PDL1P imaging agent

Group B: 68Ga-PDL1P and 18F-FDG PET imaging group:Injection of 68Ga-PDL1P imaging agent

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >=18 years old, male or female not limited; 2.Research participants have behavioral capacity, understand and have voluntarily signed informed consent forms; 3.Patients with initial diagnosis of malignant tumors or previously diagnosed malignant tumors undergoing concurrent treatment;

Exclusion criteria

Exclusion criteria: 1.Critically ill patients requiring emergency treatment; 2.Drug and/or alcohol abusers, individuals with allergies; 3.Pregnant, lactating, and pre pregnancy women; 4.There are bacterial, viral, or fungal infections that require systemic treatment; 5.Participants deemed unsuitable by researchers;

Design outcomes

Primary

Measure	Time frame
The maximum standardized uptake value;	—

Countries

China

Contacts

Public ContactFu Wei

The First Affiliated Hospital of Guilin Medical University

13977385850@126.com+86 13977385850

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026